Systemic vasculitis associated with vemurafenib treatment: Case report and literature review

RATIONALE: Vemurafenib, an inhibitor of mutated B-rapidly accelerated fibrosarcoma, is frequently used in the treatment of melanoma and Erdheim–Chester disease (ECD) patients. Inflammatory adverse effects have been increasingly reported after vemurafenib treatment. PATIENT CONCERNS AND DIAGNOSE: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirouse, Adrien, Savey, Léa, Domont, Fanny, Comarmond, Cloé, Barete, Stéphane, Plaisier, Emmanuelle, Rouvier, Philippe, Cacoub, Patrice, Saadoun, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
3600
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120889/
https://www.ncbi.nlm.nih.gov/pubmed/27861332
http://dx.doi.org/10.1097/MD.0000000000004988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120889/
https://www.ncbi.nlm.nih.gov/pubmed/27861332
http://dx.doi.org/10.1097/MD.0000000000004988

Ejemplares similares